Trial Profile
A randomized, controlled, multi-center study evaluating combined operation modality vs imatinib alone (COMVIA) in patients with recurrent/metastatic c-kit positive gastrointestinal stromal tumor
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 21 May 2012 Planned end date (30 May 2011) added as reported by Chinese Clinical Trial Register.
- 05 Dec 2011 New trial record